Last reviewed · How we verify

NCT02618343

EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron

Completed NA Results posted Last updated 24 March 2021
What this trial tests

NA trial testing IPA in Nausea in 51 participants. Completed in 1 March 2019.

Timeline
4 October 2016
Primary endpoint
1 March 2019
1 March 2019

Quick facts

Lead sponsorThe University of Texas Health Science Center at San Antonio
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment51
Start date4 October 2016
Primary completion1 March 2019
Estimated completion1 March 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

The University of Texas Health Science Center at San Antonio

Who can join

Adults 18 to 99, any sex, with Nausea. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Time to Nausea Reduction by 50% by Visual Analog Scale. Primary · Baseline and up to 10 minutes

A visual analog scale (VAS) will be utilized to determine level of nausea. The VAS scale will be utilized before enrollment, at the time of medication administration, then every 2 minutes after administration for 10 minutes. The scale is a numbered linear scale from 0-10, with 0 = no nausea and 10 = worst nausea possible

GroupValue95% CI
Isopropyl Alcohol4.3± 3.1
Ondansetron Group3.5± 2.9
Number of Subjects That Required Rescue Ondansetron Secondary · 15 minutes

We will compare the number of times that a subject required ondansetron administration after IPA administration, and the number of times ondansetron repeat dose is required in the control group.

GroupValue95% CI
Isopropyl Alcohol0
Ondansetron Group2

Sponsor's own description

Nausea is a common symptom encountered in the Emergency Medical Services (EMS) environment that is often treated with oral or intravenous anti-emetic medications. Research Design/Plan: This will be a randomized equivalence study comparing the reduction in a patient's reported level of nausea after treatment with either Ondansetron or IPA Methods: Patients who report nausea and/or vomiting in the normal evaluation and care of after calling 911 for Emergency Medical Care will be offered enrollment in the study. A short script will be attached to the outside of each study packet providing information about the study and its risks and benefits. Verbal or written (waiver of informed consent will be requested) permission will be obtained to start randomization. If the patient agrees to enroll then the study packet will be opened and utilized. All Advanced Life Support Ambulances in the San Antonio Fire Department will have sealed numbered opaque boxes or envelopes with either: 70% Isopropyl Alcohol swabs or ondansetron. Six Visual Nausea Severity Scoring cards will be provided with a marking pen to record timed nausea levels before and upon arrival to the Emergency Department and 15 minutes after treatment whichever comes first. Clinical Relevance: This treatment has not been studied in the unique environment encountered by Paramedics in the Pre-Hospital setting. If this treatment is found to be effective, it many offer a very simple, extremely inexpensive and non-invasive (basic life support) approach for the treatment of nausea.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Nausea

Currently open trials in the same condition.

Other The University of Texas Health Science Center at San Antonio trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02618343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing